Key result
Diminazene aceturate (15 mg/kg) significantly increased brain Ang-(1-7) levels to 120.60 pg/mg compared to 44.49 pg/mg in vehicle-treated SAMP8 mice, ameliorating AD-like neuropathology and cognitive impairment.
Why the study?
Does diminazene aceturate improve AD-like neuropathology and cognitive impairment in SAMP8 mice?
Does diminazene aceturate improve AD-like neuropathology and cognitive impairment in SAMP8 mice?
The ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and cognitive impairment in SAMP8 mice, highlighting the brain ACE2/Ang-(1-7)/MAS1 axis as a potential therapeutic target for sporadic AD.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ACE2 activation in neurodegeneration; leaves open translation to human Alzheimer's therapy.
, hyperphosphorylated tau and pro-inflammatory cytokines in the brain. The synaptic and neuronal losses in the brain were ameliorated by DIZE. Importantly, DIZE improved spatial cognitive functions in the Morris water maze test. In conclusion, this study demonstrates that DIZE ameliorates AD-like neuropathology and rescues cognitive impairment in SAMP8 mice. These beneficial effects of DIZE may be achieved by activating brain ACE2/Ang-(1-7)/MAS1 axis. These findings highlight brain ACE2/Ang-(1-7)/MAS1 axis as a potential target for the treatment of sporadic AD.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2020) studied Alzheimer's disease (animal model). Diminazene aceturate (DIZE) vs. Vehicle (0.9% sterile saline) was evaluated on Brain Ang-(1-7) levels (p=<0.05). Diminazene aceturate (15 mg/kg) significantly increased brain Ang-(1-7) levels to 120.60 pg/mg compared to 44.49 pg/mg in vehicle-treated SAMP8 mice, ameliorating AD-like neuropathology and cognitive impairment.
Synapse has enriched 10 related papers. Consider them for comparative context: